Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
inFour Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the…